ptx3, a key component of innate immunity, is induced by saa via fprl1-mediated signaling in HAECs

Serum amyloid A (SAA) is regarded as an important acute phase protein in coronary artery diseases. However, its involvement in the immune response of atherosclerosis is poorly understood. The present study was designed to investigate the influence of SAA on the secretion of long pentraxin 3 (PTX3),...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cellular biochemistry 2011-08, Vol.112 (8), p.2097-2105
Hauptverfasser: Dong, Zhe, An, Fengling, Wu, Tingting, Zhang, Cheng, Zhang, Mingxiang, Zhang, Yun, An, Guipeng, An, Fengshuang
Format: Artikel
Sprache:eng
Schlagworte:
JNK
SAA
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Serum amyloid A (SAA) is regarded as an important acute phase protein in coronary artery diseases. However, its involvement in the immune response of atherosclerosis is poorly understood. The present study was designed to investigate the influence of SAA on the secretion of long pentraxin 3 (PTX3), a key component of innate immunity, in human aortic endothelial cells (HAECs). Our study revealed that recombinant SAA up‐regulated PTX3 production in a remarkable dose‐ and time‐dependent manner and the activation of formyl peptide receptor‐like 1 (FPRL1) was crucial for SAA‐induced expression of PTX3 in HAECs. Meanwhile, SAA‐induced PTX3 production could be significantly down‐regulated by using the specific siRNA sequences for Jun N‐terminal kinases (JNK). Furthermore, the activation of activator protein‐1 (AP‐1) was necessary for the up‐regulation of PTX3 expression. We also found that the activation of nuclear factor‐kappa B (NF‐κB) played an important role in this process. Our findings demonstrate that SAA up‐regulates PTX3 production via FPRL1 significantly, and thus, contributes to the inflammatory pathogenesis of atherosclerosis. J. Cell. Biochem. 112: 2097–2105, 2011. © 2011 Wiley‐Liss, Inc.
ISSN:0730-2312
1097-4644
DOI:10.1002/jcb.23128